Skip to content
X-twitter Linkedin Youtube
  • FR
  • EN
  • FR
  • EN
  • HERV Approach
    • A novel approach
    • HERV in MS
    • HERV in Post-COVID
    • HERV in ALS
    • Other HERV-mediated diseases
    • Pipeline Overview
    • Intellectual Property
  • Post-COVID
    • HERV in Post-COVID
    • Clinical trial
    • Publications
  • Clinical Trials
  • News & Media
    • News & Press
    • Scientific publications
  • Investors
    • GNRO Shares
    • GeNeuro’s main shareholders
    • Analyst coverage
    • Stock price
    • Press releases
    • Annual reports / Registration documents
    • AMF Regulated information
    • Company governance
    • Financial events
    • Investor relations
  • About GeNeuro
    • Company Overview
    • Company History
    • The Board of GeNeuro
    • Management
    • General meetings
  • Contact
Menu
  • HERV Approach
    • A novel approach
    • HERV in MS
    • HERV in Post-COVID
    • HERV in ALS
    • Other HERV-mediated diseases
    • Pipeline Overview
    • Intellectual Property
  • Post-COVID
    • HERV in Post-COVID
    • Clinical trial
    • Publications
  • Clinical Trials
  • News & Media
    • News & Press
    • Scientific publications
  • Investors
    • GNRO Shares
    • GeNeuro’s main shareholders
    • Analyst coverage
    • Stock price
    • Press releases
    • Annual reports / Registration documents
    • AMF Regulated information
    • Company governance
    • Financial events
    • Investor relations
  • About GeNeuro
    • Company Overview
    • Company History
    • The Board of GeNeuro
    • Management
    • General meetings
  • Contact
  • GNRO Shares
  • GeNeuro’s main shareholders
  • Analyst coverage
  • Stock price
  • Press releases
  • Presentations
  • Annual reports / Registration documents
  • AMF Regulated information
  • Company governance
  • General meetings
  • Financial events
  • Investor relations
  • GNRO Shares
  • GeNeuro’s main shareholders
  • Analyst coverage
  • Stock price
  • Press releases
  • Presentations
  • Annual reports / Registration documents
  • AMF Regulated information
  • Company governance
  • General meetings
  • Financial events
  • Investor relations

Annual reports / Registration documents

  • 2023 Universal Registration Document
  • 2022 Consolidated financials (XHTML)
  • 2022 Universal Registration Document
  • Update to the 2021 Universal Registration Document
  • Universal Registration Document (XHTML)
  • 2021 Universal Registration Document
  • 2021 Universal Registration Document
  • 2021 Universal Registration Document
  • 2020 Universal Registration Document
  • 2019 Universal Registration Document
  • Registration Document 2018 - nr. R.19-017
  • Registration Document 2017 - nr. R.18-031
  • Free translation of 2016 Reference Document
  • GeNeuro SA - French IPO prospectus (in French)

© 2025 GeNeuro SA

  • Legal Notice

 3, Chemin du Pré-Fleuri
CH-1228 Plan-les-Ouates
Geneva, Switzerland

  • contact@geneuro.com
X-twitter Linkedin Youtube